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Abstract 
Pharmacologically-induced pre- and post-conditioning represent attractive therapeutic 
strategies to reduce ischaemia/reperfusion injury during cardiac surgery and following 
myocardial infarction. We have previously reported that transglutaminase 2 (TG2) activity is 
modulated by the A1 adenosine receptor and β2-adrenoceptor in H9c2 cardiomyoblasts. The 
primary aim of this study was to determine the role of TG2 in A1 adenosine receptor and β2-
adrenoceptor-induced pharmacological pre- and post-conditioning in the H9c2 cells. H9c2 
cells were exposed to 8 h hypoxia (1% O2) followed by 18 h reoxygenation, after which cell 
viability was assessed by monitoring mitochondrial reduction of MTT, lactate dehydrogenase 
release and caspase-3 activation. N6-cyclopentyladenosine (CPA; A1 adenosine receptor 
agonist), formoterol (β2-adrenoceptor agonist) or isoprenaline (non-selective β-
adrenoceptor agonist) were added before hypoxia/reoxygenation (pre-conditioning) or at 
the start of reoxygenation following hypoxia (post-conditioning). Pharmacological pre- and 
post-conditioning with CPA and isoprenaline significantly reduced hypoxia/reoxygenation-
induced cell death. In contrast, formoterol did not elicit protection. Pre-treatment with 
pertussis toxin (Gi/o-protein inhibitor), DPCPX (A1 adenosine receptor antagonist) or TG2 
inhibitors (Z-DON and R283) attenuated the A1 adenosine receptor-induced pharmacological 
pre- and post-conditioning. Similarly, pertussis toxin, ICI 118,551 (β2-adrenoceptor 
antagonist) or TG2 inhibition attenuated the isoprenaline-induced cell survival. Knockdown 
of TG2 using small interfering RNA (siRNA) attenuated CPA and isoprenaline-induced 
pharmacological pre- and post-conditioning. Finally, proteomic analysis following 
isoprenaline treatment identified known (e.g. protein S100-A6) and novel (e.g. adenine 
phosphoribosyltransferase) protein substrates for TG2. These results have shown that A1 
adenosine receptor and β2-adrenoceptor-induced protection against simulated 
hypoxia/reoxygenation occurs in a TG2 and Gi/o-protein dependent manner in H9c2 
cardiomyoblasts. 
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1. Introduction 
Ischaemic preconditioning or classical pre-conditioning is a well-characterized phenomenon 
in which transient exposure to ischaemia protects the myocardium from infarction induced 
by a subsequent and prolonged ischaemic attack (Murry et al. 1986). Ischaemic post-
conditioning is a more recently identified cardioprotective phenomenon, which involves brief 
periods of ischaemia applied during the start of reperfusion, after a prolonged ischaemic 
insult (Zhao et al. 2003). The molecular mechanisms underlying ischaemic pre-/post-
conditioning have been extensively studied, resulting in a number of membrane-bound 
receptors, predominantly belonging to the G protein-coupled receptor (GPCR) superfamily, 
being implicated in cardioprotection including the A1 adenosine receptor (Sommerschild and 
Kirkebøen 2000; Headrick et al. 2003; Peart and Headrick 2007; Fretwell and Dickenson 
2009; Urmaliya et al. 2009) and the β2-adrenoceptor (Tong  et al. 2005; Gross and Gross, 
2006; Salie et al. 2011; Salie et al. 2012). Direct stimulation of the aforementioned 
receptors or pharmacological activation of signalling pathways associated with them can 
mimic the cardioprotective effects of ischaemic pre- and post-conditioning (Burley and 
Baxter 2009; Sanada et al. 2011; Cohen and Downey, 2015; Hausenloy and Yellon, 2016). 
 
The signal transduction mechanisms triggered by the A1 adenosine receptor and β2-
adrenoceptor include several protein kinases, such as protein kinase C (PKC; Henry et al. 
1996), protein kinase B (PKB; Chesley et al. 2000; Germack et al. 2004) and extracellular-
signal-regulated kinase 1/2 (ERK1/2; Schmitt and Stork, 2000; Germack and Dickenson, 
2005; Shenoy et al. 2006). These pro-survival kinases belong to the Reperfusion Injury 
Salvage Kinase (RISK) pathway, which when activated promotes cardioprotection 
(Hausenloy and Yellon, 2007). It is interesting to note ERK1/2,  a prominent member of the 
RISK pathway, is involved in A1 adenosine receptor and β2-adrenoceptor-induced tissue 
transglutaminase (TG2) activation (Vyas et al. 2016; Vyas et al. 2017). 
 
Transglutaminases (TGs) are a family of calcium (Ca2+) dependent enzymes (TG1-7 and 
Factor XIIIa) that catalyse the post-translational modification of proteins (Eckert et al., 
2014). TG2 is a ubiquitous member of the TG family that possess several enzymic functions 
that include transamidation, protein disulphide isomerase and protein kinase activity 
(Gundemir et al. 2012). Although TG2 has been implicated in protection of cardiomyocytes 
against ischaemia/reperfusion injury by regulating ATP synthesis, at present very little is 
known regarding its potential role in pre- and post-conditioning (Szondy et al. 2006). We 
have recently shown that TG2 activity can be modulated by the A1 adenosine receptor and 
β2-adrenoceptor in H9c2 cardiomyoblasts (Vyas et al. 2016; Vyas et al. 2017). Therefore, 
the primary aim of this study was to determine the role of TG2 in A1 adenosine receptor and 
β2-adrenocepor-induced pre- and post-conditioning against hypoxia/reoxygenation-induced 
cell death in H9c2 cells. The results obtained indicate for the first time that TG2 plays an 
anti-apoptotic role in the A1 adenosine receptor and β2-adrenocepor-induced 
pharmacological pre- and post-conditioning in H9c2 cells.  It is conceivable that TG2 is a 
downstream effector of the Reperfusion Injury Salvage Kinase pathway and as such TG2-
induced post-translational modification of mitochondrial proteins that are associated with 
cell death/survival may play a prominent role in cardioprotection. 
  
2. Materials and methods 
 
2.1. Materials 
Formoterol, forskolin, ICI 118,551 ((±)-erythro-(S*,S*)-1-[2,3-(Dihydro-7-methyl-1H-
inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride), PD 98059 (2-(2-
Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) and propranolol were obtained from 
Tocris Bioscience (Bristol, UK). DPCPX (1,3-dipropylcyclopentylxanthine), IBMX (3-isobutyl-
1-methylxanthine) isoprenaline, MTT (3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide), N′,N′-dimethylcasein, N6-cyclopentyladenosine (CPA), pertussis toxin, protease 
inhibitor cocktail, phosphatase inhibitor cocktail 2 and horseradish peroxidase conjugated 
ExtrAvidin® (ExtrAvidin®-HRP) were obtained from Sigma-Aldrich Co. Ltd. (Gillingham, 
Dorset, UK). The TG2 inhibitors Z-DON (Z-ZON-Val-Pro-Leu-OMe; Benzyloxycarbonyl-(6-
Diazo-5-oxonorleucinyl)-L-valinyl-L-prolinyl-L-leucinmethylester) and R283 (1,3,dimethyl-
2[2-oxo-propyl]thio)imidazole chloride) along with purified standard guinea-pig liver TG2 
were obtained from Zedira GmbH (Darmstadt, Germany). Biotin cadaverine (N-(5-
aminopentyl)biotinamide) was purchased from Invitrogen UK (Loughborough, UK). CytoTox 
96 non-radioactive cytotoxicity assay kit was from Promega (Southampton, UK). DMEM 
(Dulbecco´s modified Eagle´s medium), foetal bovine serum, trypsin (10X), L-glutamine 
(200 mM), penicillin (10,000 U/ml)/streptomycin (10,000 g/ml) were purchased from 
Lonza, (Castleford, UK). All other chemicals were of analytical grade. Antibodies were 
obtained from the following suppliers: polyclonal anti-cleaved caspase-3 (Asp175) and 
monoclonal anti-GAPDH were purchased from New England Biolabs Ltd. (Hitchin, UK);  anti-
protein S100-A6 antibody was obtained from Abcam (Cambridge, UK); monoclonal  anti-
transglutaminase 2 (CUB 7402) and monoclonal β-actin from ThermoFisher Scientific 
(Loughborough, UK).  
 
 
 2.2. Cell culture 
Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). It is important to note that 
H9c2 cells, derived from embryonic rat heart tissue (Kimes and Brandt, 1976), are 
increasingly used as an in vitro model for studies exploring cardioprotection since they 
display similar morphological, electrophysiological and biochemical properties to primary 
cardiac myocytes (Hescheler et al. 1991). Furthermore, recent studies have demonstrated 
that H9c2 cells are energetically more similar to primary cardiac myocytes than mouse atrial 
HL-1 cells and thus represent a viable in vitro model to investigate simulated cardiac 
ischaemia/reperfusion injury (Kuznetsov et al. 2015). In addition to their increasing use in 
studies exploring cardioprotection, H9c2 cells show hypertrophic responses comparable to 
primary neonatal cardiac myocytes and therefore also represent a useful cell model system 
to study heart disease (Watkins et al. 2011).  Cells were cultured in Dulbecco's modified 
Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine, 10% (v/v) foetal bovine 
serum and penicillin (100 U/ml)/streptomycin (100 g/ml). Cells were maintained in a 
humidified incubator (95% air/5% CO2 at 37°C) until 70-80% confluent and sub-cultured 
(1:5 split ratio) using trypsin (0.05% w/v)/EDTA (0.02% w/v). 
 
2.3. cAMP accumulation assay 
H9c2 cells (5000 cells/well) were seeded on a white 96 well microtitre plate, with clear-
bottomed wells (Fisher Scientific, Loughborough, UK) and cultured for 24 h in fully 
supplemented DMEM. The medium was removed and the monolayer treated with a range of 
concentrations of formoterol for 20 min in serum-free DMEM (40 µl/well) in the presence of 
20 mM MgCl2 and 500 µM IBMX. Following stimulation, cAMP levels within cells were 
determined using the cAMP-Glo™ Max Assay kit (Promega UK, Southampton, UK). Briefly, 
10 µl of cAMP detection solution were added to all wells and incubated for 20 min at room 
temperature. After incubation, Kinase-Glo® reagent (50 µl/well) was added and incubated 
for 10 min at room temperature, following which luminescence levels across the plate were 
read using a plate-reading FLUOstar Optima luminometer (BMG Labtech Ltd, Aylesbury, 
UK). Forskolin (10 µM) was used as a positive control and the luminescence values were 
converted to cAMP levels using a cAMP standard curve (0-100 nM), according to the 
manufacturer’s instructions. 
 
2.4. Transglutaminase activity assays 
Time course profiles and concentration-response curves were obtained for isoprenaline. 
Following stimulation, cells were rinsed twice with 2.0 ml of chilled PBS, lysed with 500 μl of 
ice-cold lysis buffer (50 mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/v) 
protease inhibitor cocktail, and 1% (v/v) phosphatase inhibitor cocktail 2 and 3). Cell 
lysates were clarified by centrifugation at 4°C for 10 min at 14,000 x g prior to being 
assayed for TG activity, as described below. Protein was determined using the bicinchoninic 
acid (BCA) protein assay (Smith et al, 1985), using a commercially available kit (Sigma-
Aldrich Co. Ltd), with bovine serum albumin (BSA) as the standard. 
   Biotin-labelled cadaverine incorporation assays were performed according to Slaughter et 
al. (1992) with the modifications reported by Lilley et al. (1998). Briefly, 96-well microtitre 
plates were coated overnight at 4°C with 250 µl of N′,N′-dimethylcasein (10 mg/ml in 100 
mM Tris-HCl, pH 8.0). The plate was washed twice with distilled water, blocked with 250 μl 
of 3% (w/v) BSA in 100 mM Tris-HCl, pH 8.0 and incubated for 1 h at room temperature. 
The plate was washed twice before the application of 150 µl of either 6.67 mM calcium 
chloride or 13.3 mM EDTA (used to check background TG2 activity) assay buffer containing 
225 µM biotin-cadaverine (a widely used substrate to monitor TG amine incorporating 
activity) and 2 mM 2-mercaptoethanol. The reaction was started by the addition of 50 μl of 
sample, positive control (50 ng/well of guinea-pig liver TG2) or negative control (100 mM 
Tris-HCl, pH 8.0). After incubation for 1 h at 37°C, plates were washed as before. Then, 200 
μl of 100 mM Tris-HCl pH 8.0 containing 1% (w/v) BSA and ExtrAvidin®-HRP (1:5000 
dilution) were added to each well and the plate incubated at 37°C for 45 min; it was then 
washed as before. The plate was developed with 200 μl of freshly prepared developing 
buffer (7.5 µg/ml 3, 3´, 5, 5´-tetramethylbenzidine and 0.0005% (v/v) H2O2 in 100 mM 
sodium acetate, pH 6.0) and incubated at room temperature for 15 min. The reaction was 
terminated by adding 50 μl of 5.0 M sulphuric acid and the absorbance read at 450 nm. One 
unit of transglutaminase activity was defined as a change in A450 of 1.0 per hour. Each 
experiment was performed in triplicate. 
 
2.5. Hypoxia-reoxygenation-induced cell death  
H9c2 cells in glucose-free and serum-free DMEM were exposed to 8 h hypoxia using a 
hypoxic incubator (5% CO2/1% O2 at 37°C), where O2 was replaced by N2. Following 
hypoxic exposure, cells were reoxygenated in DMEM containing 1% foetal bovine serum for 
18 h in a humidified incubator (95% air/5% CO2 at 37°C). For pharmacological pre- and 
post-conditioning, cells were exposed to either CPA (100 nM; A1 adenosine receptor agonist; 
10 min), formoterol (1 µM; selective β2-adrenoceptor agonist; 20 min) or isoprenaline (10 
µM; non-selective β-adrenoceptor agonist; 20 min) either before hypoxia/reoxygenation 
(pre-conditioning) or at the start of reoxygenation following 8 h hypoxic exposure (post-
conditioning). Where appropriate, cells were treated as follows: for 30 min with DPCPX (1 
μM; A1 adenosine receptor antagonist), ICI 118,551 (1 µM; selective β2-adrenoceptor 
receptor antagonist) or propranolol (1 µM; non-selective β-adrenoceptor antagonist); for 1 
h with TG2 inhibitors Z-DON (150 μM; Schaertl et al. 2010) or R283 (200 μM; Freund et al. 
1994) or for 48 h with 1 µM TG2 siRNA or negative control siRNA before the addition of the 
appropriate agonist. After the above treatments, the medium containing agonists and 
inhibitors was removed and replaced with either fresh glucose-free/ serum-free DMEM for 
hypoxia or fresh DMEM containing normal glucose and 1% (v/v) foetal bovine serum for the 
remainder of the reoxygenation period. 
 
2.6. MTT assay 
H9c2 cells were plated in 24-well flat bottomed plates (15,000 cells per well) and cultured 
for 24 h in fully supplemented DMEM prior to hypoxia/reoxygenation. Cell viability was 
determined by measuring the metabolic reduction of MTT to a coloured formazan product. 
Cells were incubated for 1 h in 0.5 mg ml-1 MTT (added during the last hour of 
reoxygenation), after which the medium was removed and replaced with 500 l DMSO. The 
reduction reaction was measured at 570 nm. Each experiment was performed in 
quadruplicate. 
 
2.7. Lactate dehydrogenase assay 
H9c2 cells were plated in 96-well flat bottomed plates (5,000 cells per well) and cultured for 
24 h in fully supplemented DMEM prior to hypoxia/reoxygenation. Following 
experimentation, the activity of lactate dehydrogenase (LDH) released into the culture 
medium was detected using the CytoTox 96®non-radioactive cytotoxicity assay (Promega, 
Southampton, UK). Assays were performed according to the manufacturer’s instructions and 
monitored at 490 nm. Each performed was performed in sextuplicate. 
 
2.8. Western blot analysis of cleaved caspase-3 activity and TG2 expression 
Protein extracts (20-30 μg per lane) were separated by SDS-PAGE (12% polyacrylamide gel 
for caspase-3 and 10% polyacrylamide gel for TG2) using a Bio-Rad Mini-Protean III 
system. Proteins were transferred to nitrocellulose membranes in a Bio-Rad Trans-Blot 
system using 25 mM Tris, 192 mM glycine pH 8.3 and 20% (v/v) MeOH). Following transfer, 
the membranes were washed with Tris-buffered saline (TBS) and blocked for 1 h at room 
temperature with 3% (w/v) skimmed milk powder in TBS containing 0.1% (v/v) Tween-20. 
Blots were then incubated overnight at 4oC in blocking buffer with the following primary 
antibodies: cleaved caspase-3 (1:500), GAPDH (1:1000), TG2 (1:500) or β-actin (1:1000). 
The primary antibodies were removed and blots washed three times for 5 min in TBS/Tween 
20. Blots were then incubated for 2 h at room temperature with the appropriate secondary 
antibody (1:1000) coupled to horseradish peroxidase (New England Biolabs (UK) Ltd) in 
blocking buffer. Following removal of the secondary antibody, blots were extensively 
washed as above and developed using the Enhanced Chemiluminescence Detection System 
(Uptima, Interchim, France) and quantified by densitometry using Advanced Image Data 
Analysis Software (Fuji; version 3.52). The uniform transfer of proteins to the nitrocellulose 
membrane was routinely monitored by transiently staining the membranes with Ponceau S 
stain prior to application of the primary antibody.  
 
2.9. Knockdown of endogenous TG2 with siRNA 
H9c2 cells were transfected with anti-TG2 (catalogue number: A-092775-15-0005) or 
negative control siRNA (catalogue number: D-001910-01-05) at 1 µM for 48 h according to 
the manufacturer’s protocol (Dharmacon, Cambridge, UK). Briefly, fully supplemented 
DMEM cell culture medium was removed and replaced with Accell delivery medium 
containing either TG2-specific siRNA targeting the open reading frame of rat TG2 mRNA or 
negative control (non-targeting) siRNA.  
 
2.10. Proteomic analysis of TG2 biotin-X-cadaverine labelled substrate proteins 
Cellular proteins acting as substrates for endogenous TG2-catalysed polyamine 
incorporation reactions were investigated as described by Singh et al. (1995). Cells were 
labelled with biotin-X-cadaverine (1 mM; 6 h) prior to stimulation with isoprenaline (10 µM; 
20 min). Following stimulation with isoprenaline, cells were rinsed twice with 2 ml of chilled 
PBS and lysed with 500 μl of ice-cold lysis buffer (50 mM Tris-HCl pH 8.0, 0.5% (w/v) 
sodium deoxycholate, 0.1% (v/v) protease inhibitor cocktail, and 1% (v/v) phosphatase 
inhibitor cocktail 2 and 3). Cell lysates were clarified by centrifugation at 4°C for 10 min at 
14,000 x g. Biotin-X-cadaverine labelled proteins were enriched using CaptAvidin™-agarose 
sedimentation beads (Life Technologies, Loughborough, UK) and processed for trypsin 
digestion (Trypsin, proteomics grade; Sigma-Aldrich, UK).  
    Samples (~50 µg protein) were reduced and alkylated (1 µl 0.5 M DTT, 56° C for 20 min; 
2.7 µl 0.55 M iodoacetamide, room temperature 15 min in the dark), dried in a vacuum 
concentrator (Eppendorf, UK) and resuspended in 100 µl 50 mM tri-ethyl ammonium 
bicarbonate (TEAB).  Trypsin (2 µg in 2 µl of 1 mM HCl), was added in and incubated 
overnight at 37° C in a thermomixer.  Samples were then evaporated to dryness in a 
vacuum concentrator and resuspended in 5% (v/v) acetonitrile/0.1% (v/v) formic acid (20 
µl) and transferred to a HPLC vial for MS analysis. Samples (3 µl) were injected by 
autosampler (Eksigent nanoLC 425 LC system) at 5 µl/min directly onto a YMC Triart-C18 
column (25 cm, 3 µm, 300 µm i.d.) using gradient elution (2-40% Mobile phase B, followed 
by wash at 80% B and re-equilibration) over either 110 (120 min run time) min (for 
spectral library construction using data/information dependent acquisition DDA/IDA) or 50 
min (60 min run time) for SWATH/DIA (Data Independent Acquisition) analysis (Gillet et al., 
2012; Huang et al., 2015). Mobile phases consisted of A: 2% (v/v) acetonitrile, 5% (v/v) 
DMSO in 0.1% (v/v) formic acid; B: acetonitrile containing 5% (v/v) DMSO in 0.1% (v/v) 
formic acid.  
   A spectral library was constructed using the output from ProteinPilot 5 (SCIEX) combining 
four IDA runs per group (Control, formoterol treated), filtered, and aligned to spiked-in iRT 
peptides (Biognosys, Switzerland) using PeakView 2.2 (SCIEX) and the SWATH micro app 
2.1 plug in.  SWATH data extraction, quantitation and fold change analysis were carried out 
using SCIEX OneOmics cloud processing software (Lambert et al., 2013).  
 
 
  
2.11. Validation of biotinylated TG2 substrates 
The enriched biotin-X-cadaverine labelled proteins (500 µg) were incubated overnight at 
4°C with 2 µg of rabbit anti-protein S100-A6 antibody. Immune complexes were 
precipitated using Pierce™ Classic Magnetic IP/Co-IP Kit (Loughborough, UK). Precipitated 
proteins were resolved by SDS-PAGE (15% polyacrylamide gel), transferred to nitrocellulose 
and probed with ExtrAvidin®-HRP (1:5000 dilution).  Reactivity was visualised using the 
Enhanced Chemiluminescence Detection System (Uptima, Interchim, France) and quantified 
densitometrically, as described above. 
 
2.12. Data analysis 
All graphs and statistics (two-way ANOVA followed by Dunnet's multiple comparison test) 
were performed using GraphPad Prism® software (GraphPad Software, Inc., USA). Results 
represent mean ± S.E.M. and p values <0.05 were considered statistically significant. 
  
3. Results 
In this study the optimal duration of hypoxia and reoxygenation was determined by 
monitoring cell viability using MTT reduction, LDH release and caspase-3 activation (data 
not shown). Based upon these findings, a time course of 8 h of hypoxia followed by 18 h 
reoxygenation was chosen for further experiments since it produced a significant loss in cell 
viability as well as significant activation of caspase-3, indicating that apoptosis had occurred 
(data not shown). 
 
3.1. Role of TG2 in A1 adenosine receptor-induced pre-conditioning in H9c2 cells 
We have previously reported that the A1 adenosine receptor triggers pharmacological pre- 
conditioning against hypoxia-induced cell death in H9c2 cells (Fretwell and Dickenson, 2009, 
Vyas et al. 2016). In this study we have explored the role of TG2 in A1 adenosine receptor 
mediated pre-conditioning against hypoxia/reoxygenation-induced cell death. The selective 
A1 adenosine receptor agonist CPA and antagonist DPCPX were used to explore A1 adenosine 
receptor-mediated pharmacological pre-conditioning. H9c2 cells were pharmacologically pre-
conditioned with CPA (100 nM) for 10 min prior to 8 h hypoxia followed by 18 h of 
reoxygenation.  Hypoxia/reoxygenation-induced reduction of MTT and release of LDH was 
significantly reduced by CPA (Fig. 1). Furthermore, pre-treatment with DPCPX (1 µM) 
reversed CPA-induced protection (Fig. 1), confirming the involvement of the A1 adenosine 
receptor. Since MTT reduction and LDH release do not discriminate between apoptotic and 
necrotic forms of cell death, caspase 3 activity was monitored by Western blotting using an 
anti-active caspase 3 antibody, as a marker of apoptotic cell death. Hypoxia/reoxygenation-
induced caspase-3 activity was significantly reduced by CPA (Fig. 1). The role of TG2 in A1 
adenosine receptor-induced pre-conditioning was explored using pharmacological inhibitors 
of TG2 (Z-DON and R283) and knockdown of endogenous TG2 by siRNA. Transfection of 
H9c2 cells with TG2 siRNA significantly inhibited TG2 protein expression (Fig. 2). Pre-
treatment with TG2 inhibitors (either Z-DON (150 µM) or R283 (200 µM)) or transfection of 
cells for 48 h with TG2 siRNA reversed CPA-induced protection, confirming the involvement 
of TG2 in A1 adenosine receptor-induced pre-conditioning (Fig. 3). Finally, pre-treatment 
with pertussis toxin (16 h; 100 ng/ml) attenuated CPA-induced pre-conditioning, confirming 
Gi/o-protein coupling of the A1 adenosine receptor (data not shown). Overall these data 
indicate a prominent role for TG2 in A1 adenosine receptor-induced pre-conditioning. 
 
3.2. Role of TG2 in A1 adenosine receptor-induced post-conditioning in H9c2 cells 
We have previously reported that the A1 adenosine receptor triggers pharmacological post- 
conditioning against hypoxia/reoxygenation-induced LDH release (Fretwell and Dickenson, 
2011). In this study, H9c2 cells were pharmacologically post-conditioned with CPA (100 nM) 
for 10 min at the start of 18 h of reoxygenation.  Hypoxia/reoxygenation-induced reduction 
of MTT, release of LDH and activation of caspase 3 was significantly reduced following the 
addition of CPA at the onset of reoxygenation (Fig. 4). Furthermore, pre-treatment with 
DPCPX (1 µM) reversed CPA-induced post-conditioning (Fig. 4). Pharmacological inhibition of 
TG2 (Z-DON (150 µM) and R283 (200 µM)) and TG2 siRNA reversed CPA-induced 
protection, indicating the involvement of TG2 in A1 adenosine receptor-induced post-
conditioning (Fig. 5). Finally, pre-treatment with pertussis toxin attenuated CPA-induced 
post-conditioning (data not shown). Overall these data indicate a prominent role for TG2 in 
A1 adenosine receptor-induced post-conditioning. 
 
3.3. Role of TG2 in β2-adrenoceptor-induced pre-conditioning in H9c2 cells 
Our previous studies have indicated functional expression of the β2-adrenoceptor but not the 
β1-adrenoceptor in H9c2 cells (Vyas et al. 2017). Furthermore, the long-acting selective β2-
adrenoceptor agonist formoterol triggers TG2 transamidase activity in H9c2 cells (Vyas et 
al. 2017). It is also notable that in mouse cardiomyocytes the β2-adrenoceptor stimulates 
anti-apoptotic and pro-apoptotic pathways via Gi and Gs-protein coupling, respectively (Zhu 
et al. 2001). In this study the role of TG2 in β2-adrenoceptor-induced cell survival was 
assessed in H9c2 cells following exposure of cells to simulated hypoxia followed by 
reoxygenation. Pre-treatment with formoterol (1 µM) had no significant effect on 
hypoxia/reoxygenation-induced decrease in MTT reduction (Fig. 6A) or release of LDH (Fig. 
6B). In marked contrast, pre-treatment with the non-selective β-adrenoceptor agonist 
isoprenaline (10 µM) significantly attenuated hypoxia/reoxygenation-induced decrease in 
MTT reduction (Fig. 6C), release of LDH (Fig. 6D) and activation of caspase 3 (Fig. 6E and 
6F). Furthermore, treatment with the selective β2-adrenoceptor antagonist ICI 118,551 (1 
µM) and the non-selective β-adrenoceptor receptor antagonist propranolol (1 µM) reversed 
isoprenaline-induced protection (Fig. 6), suggesting mediation via the β2-adrenoceptor. 
Previous studies have shown that isoprenaline-induced cell survival involves Gi-protein 
coupling (Zhu et al. 2001; Salie et al. 2011). Pertussis toxin (16 h; 100 ng/ml) attenuated 
isoprenaline-induced pre-conditioning, indicative of Gi/o-protein involvement (Fig. 7).  
Finally, pharmacological inhibition of TG2 (R283 and Z-DON) and TG2 siRNA attenuated 
isoprenaline-induced cell survival (Fig. 8). Overall, these data indicate that isoprenaline-
induced β2-adrenoceptor activation triggers pharmacological pre-conditioning via a Gi/o-
protein and TG2 dependent pathway. 
   As expected, isoprenaline triggered transient (peaking at 20 min; Fig. 9A) and 
concentration dependent (Fig. 9B; EC50 = 980 nM;  p[EC50] = 6.13  0.15; n=4) increases in 
TG2 catalysed biotin-cadaverine incorporation. The antagonists ICI 118,551 and propranolol 
blocked isoprenaline-induced TG2 activation (Fig. 9C). Responses to isoprenaline were 
inhibited following pre-treatment of cells with the TG2 inhibitors Z-DON and R283 (Fig. 9D).  
TG2 responses to isoprenaline were also blocked by pertussis toxin, indicating a role for Gi/o-
proteins (Fig. 9E). We have recently shown that formoterol-induced TG2 activation involves 
ERK1/2, a component of the Reperfusion Injury Salvage Kinase pathway (Vyas et al. 2017). 
In this study, treatment with PD 98059 (MEK1/2 inhibitor; 50 µM) blocked isoprenaline-
induced TG2 activation suggesting ERK1/2 involvement (Fig. 9F). Finally, it is notable that 
isoprenaline triggers only a modest increase in cAMP (Fig. 10; EC50 = 24 nM; p[EC50] = 7.63 
 0.07; n=4). However, following treatment of cells for 16 h with pertussis toxin (100 
ng/ml), isoprenaline triggered a robust cAMP response (EC50 = 2.3 nM; p[EC50] = 8.68  
0.09; n=4). Overall, these data suggest that isoprenaline-induced activation of the β2-
adrenoceptor in H9c2 cells signals predominantly via Gi/o-proteins. 
 
3.4. Role of TG2 in β2-adrenoceptor-induced post-conditioning in H9c2 cells 
H9c2 cells were pharmacologically post-conditioned with isoprenaline (10 µM) for 20 min at 
the start of 18 h of reoxygenation.  Hypoxia/reoxygenation-induced reduction of MTT, 
release of LDH and activation of caspase 3 was significantly reduced following the addition 
of isoprenaline at the onset of reoxygenation (Fig. 11). Pre-treatment with either ICI 
118,551 (1 µM) or propranolol (1 µM) reversed isoprenaline-induced post-conditioning (Fig. 
11). Furthermore, pertussis toxin attenuated isoprenaline-induced post-conditioning 
indicative of Gi/o-protein involvement (Fig. 12). Finally, pharmacological inhibition of TG2 (Z-
DON (150 µM) and R283 (200 µM)) and TG2 siRNA reversed isoprenaline-induced 
protection, indicating the involvement of TG2 in β2-adrenoceptor-induced post-conditioning 
(Fig. 13). Overall these data indicate a prominent role for TG2 in β2-adrenoceptor-induced 
post-conditioning. 
 
3.5. Identification of biotin-X-cadaverine labelled protein substrates 
We have previously identified TG2 substrates following stimulation of the β2-adrenoceptor 
with formoterol (Vyas et al. 2017). In this study, we identified TG2 substrates following 
stimulation with isoprenaline (10 µM for 20 min). Initially, cell extracts from biotin-X-
cadaverine labelled cells (1 mM for 6h) were enriched using CaptAvidin™-agarose 
sedimentation beads. To identify the proteins captured and eluted from CaptAvidin™-
agarose beads, eluates were analysed by SWATH-MS (Sequential Windowed Acquisition of 
All Theoretical Fragment Ion Mass Spectra; Huang et al. 2015). This technique allows 
quantification of mass spectrometry data and the results presented are shown as 
isoprenaline-induced fold-changes in proteins eluted from CaptAvidin™-agarose compared to 
control unstimulated cells.  These experiments identified numerous proteins, including 
several novel TG2 substrates, whose profiles either increased or decreased following 
isoprenaline treatment (Table 1). Further work is needed to determine whether these 
changes represent altered transamidation and/or interactions with TG2 substrate binding 
partners.  
   Protein S100-A6 was chosen for validation via immunoprecipitation, SDS-PAGE and 
Western blot analysis since we recently identified this protein as a TG2 substrate that is 
transamidated following β2-adrenoceptor activation with formoterol (Vyas et al. 2017). 
Enhanced incorporation of the biotinylated amine into protein S100-A6 was shown using 
ExtrAvidin®-HRP following treatment with isoprenaline (Fig. 14). Furthermore, isoprenaline-
induced increases in biotinylated protein S100-A6 were reversed by the TG2 inhibitors Z-
DON (150 µM) and R283 (200 µM).  
  
4. Discussion 
   At present there is very little information regarding the physiological role(s) of TG2 in the 
heart. Studies employing TG2 knockout mice have revealed a role for TG2 in protecting 
against ischaemia/reperfusion injury via the regulation of mitochondrial respiratory function 
(Szondy et al. 2006). In marked contrast, TG2 triggers apoptosis in rat neonatal 
cardiomyocytes exposed to H2O2-induced oxidative stress (Song et al. 2011). These 
conflicting reports suggest the role of TG2 in cardiac myocyte cell survival/apoptosis is 
unresolved and may depend upon the model employed and the mode of stress used to 
induce cell death.  Our recent studies have shown that the A1 adenosine receptor and β2-
adrenoceptor stimulate TG2 transamidase activity in the rat embryonic cardiomyoblast-
derived cell line H9c2 (Vyas et al. 2016; Vyas et al. 2017). Furthermore, we have 
demonstrated that TG2 plays a role in A1 adenosine receptor-mediated cytoprotection 
against hypoxia-induced cell death in H9c2 cells (Vyas et al. 2016). Given the conflicting 
role of TG2 in cardiomyocyte cell survival/apoptosis we have extended our previous findings 
to investigate further the role of TG2 in A1 adenosine receptor and β2-adrenoceptor-induced 
pre- and post-conditioning against hypoxia/reoxygenation-induced cell death in H9c2 cells. 
The data presented clearly show for the first time that pharmacological inhibition and siRNA 
knockdown of TG2 attenuates the A1 adenosine receptor and β2-adrenoceptor-mediated pre- 
and post-conditioning in H9c2 cells exposed to simulated hypoxia/reoxygenation. The role of 
TG2 in protecting against hypoxia/reoxygenation-induced cell death is in agreement with 
Szondy et al. (2006). In contrast, TG2 appears to promote cardiomyocyte cell death when 
using H2O2-induced oxidative stress as the model for ischaemia/reperfusion injury (Song et 
al. 2011).    
 
4.1. A1-adenosine receptor-induced cell survival 
   The role of the A1 adenosine receptor in ischaemic pre-conditioning and associated 
signalling pathways have been widely studied in many model systems (Peart and Headrick, 
2007; McIntosh and Lasley, 2012; Headrick et al. 2013). Components of A1 adenosine 
receptor-mediated cardioprotection include PKC (Henry et al. 1996), ERK1/2 (Germack and 
Dickenson, 2005) and the large-conductance Ca2+-activated K+ channel (Fretwell and 
Dickenson, 2009). In this study we have shown a role for TG2 in mediating A1 adenosine 
receptor-induced pre-conditioning.  
   The role of the A1 adenosine receptor in ischaemic post-conditioning is controversial 
(Burley and Baxter, 2009). Evidence for a role include studies showing that the infarct 
limiting protection of ischaemic post-conditioning was absent in A1 adenosine receptor 
knockout mice (Xi et al. 2008). Likewise, the A1 adenosine receptor antagonist DPCPX 
blocked ischaemic post-conditioning in normal and hyper-cholesterolemic rabbits (Donato et 
al. 2007). Cell-based studies using rat ventricular myocytes have also demonstrated that 
pharmacological post-conditioning with adenosine is blocked by DPCPX and involves the 
mitochondrial KATP channel (Lu et al. 2006). Finally, our own work has revealed A1 
adenosine receptor-induced pharmacological post-conditioning in H9c2 cells (Fretwell and 
Dickenson 2011).  In contrast, several reports suggest that the A1 adenosine receptor is not 
involved in ischaemic post-conditioning (Kin et al. 2005; Philip et al. 2006). The reasons for 
these differences may reflect differences in experimental protocol and model systems used. 
In this study we have shown for the first time that TG2 is involved in the anti-apoptotic 
effect of A1 adenosine receptor-induced post-conditioning.  
 
4.2. β2-adrenoceptor-induced cell survival 
   In the current study, formoterol had no significant effect on hypoxia/reoxygenation-
induced decrease in MTT reduction or release of LDH. These observations contrast with 
previous studies reporting formoterol-induced cardioprotection in isolated rat hearts (Salie 
et al. 2011). The reason(s) for the discrepancy are unclear but may reflect the use of 
different models (e.g. cell line versus isolated heart) and end points (cell viability assays 
versus infarct size) employed. In marked contrast, isoprenaline, which we have shown in 
the present work to signal predominantly via Gi-protein, significantly attenuated hypoxia/re-
oxygenation-induced decrease in MTT reduction, release of LDH and caspase 3 activation via 
a TG2-dependent pathway. This is in agreement with previous studies showing that 
isoprenaline-induced cell survival involved Gi-protein coupling (Zhu et al. 2001; Salie et al. 
2011). It is important to note that in H9c2 cells formoterol induces a robust cAMP response 
with no apparent Gi/o-protein coupling (Vyas et al. 2017). However, at present it is not clear 
why formoterol does not elicit increased cell survival despite triggering TG2 activation (Vyas 
et al. 2017).  Possible explanations for this include; (i) only Gi-protein-mediated TG2 
stimulation is cytoprotective, possibly via the selective activation of alternative enzymic 
functions of TG2 (e.g. protein kinase) not activated via Gs-dependent pathways, or (ii) 
opposing effects of robust formoterol-induced cAMP signalling on cell death which 
counteract TG2-induced cell survival. Indeed, the β2-adrenoceptor triggers a pro-apoptotic 
signal in cardiomyocytes via Gs-protein dependent signalling (Zhu et al. 2001).  Overall 
these data highlight the need to carefully consider the signalling profiles (Gs versus Gi) when 
selecting β2-adrenoceptor agonists for use in studies investigating cardioprotection. 
   Finally, whilst previous studies have demonstrated β2-adrenoceptor-induced 
cardioprotection via pharmacological pre-conditioning in mouse and rat heart (Tong et al. 
2005; Bernstein et al. 2011; Salie et al. 2001), very little is known regarding β2-
adrenoceptor-induced post-conditioning. However, it is notable that the β2-adrenoceptor 
plays a role in post-conditioning mediated by the anaesthetic desflurane in rabbit heart 
(Lange et al. 2009). Hence, the data presented in this study demonstrate β2-adrenoceptor-
induced post-conditioning in a cell based model.  
 
4.3. Role of TG2 in cell survival  
   TG2 appears to have a dual role in cell survival/apoptosis with its exact function being 
dependent upon many factors including cell type, cellular location, and mode of stress 
(Fésϋs and Szondy, 2005; Tatsukawa et al. 2016). Although the A1 adenosine receptor and 
β2-adrenoceptor stimulate TG2 transamidase activity in H9c2 cells (Vyas et al. 2016; Vyas 
et al. 2017) it is not known at present if the protective roles of TG2 observed in this study 
are dependent upon its transamidase activity. Whilst the TG2 inhibitors Z-DON and R283 
blocked A1 adenosine receptor and β2-adrenoceptor-induced TG2 transamidase activity 
(Vyas et al. 2016; Vyas et al. 2017) it is conceivable that the protective effects of TG2 are 
mediated via the protein disulphide isomerase and/or protein kinase functions of TG2. It is 
not known if Z-DON and R283 inhibit the protein disulphide isomerase and/or protein kinase 
activity of TG2. Alternatively, the protective effects of TG2 may relate to the non-enzymatic 
functions of TG2 (e.g. adapter protein and cell signalling regulator), although this would 
seem unlikely given the effects of Z-DON and R283 on A1 adenosine receptor and β2-
adrenoceptor-induced cell survival.   
   Whilst A1 adenosine receptor and isoprenaline-induced TG2 transamidase activity is 
dependent upon Gi/o-protein coupling, at present the precise signal transduction 
mechanism(s) linking Gi/o-protein and TG2 activation is unclear. However, it would seem 
unlikely that stimulation of TG2 involves direct activation via Gi and/or Gβ subunits. Our 
previous studies have shown that TG2 is phosphorylated in response to A1 adenosine 
receptor and β2-adrenoceptor activation via a pathway involving ERK1/2 (Vyas et al. 2016; 
Vyas et al. 2017). However, at present it is not known if A1 adenosine receptor and β2-
adrenoceptor-induced TG2 activity is dependent upon TG2 phosphorylation. Finally, since 
the A1 adenosine receptor and isoprenaline trigger ERK1/2 activation in H9c2 cells via a Gi/o-
protein dependent pathway (data not shown) it is likely that TG2 activation proceeds via 
this route. 
   Cell death induced by hypoxia/reoxygenation is mainly mediated by mitochondrial 
dysfunction and opening of the mitochondrial permeability transition pore (Assaly et al. 
2012). Hence it is likely that the cell survival role of TG2 observed in this study involves 
modulation of protein(s) associated with the intrinsic mitochondrial apoptotic pathway. For 
example, recent studies have shown that TG2 inhibits apoptosis via the down-regulation of 
Bax expression and subsequent inhibition of caspase 3 and 9 (Cho et al. 2010). 
Furthermore, we have recently identified hexokinase 1 (HK1) and voltage-dependent anion-
selective channel protein 1 (VDAC1) as TG2 protein substrates following A1 adenosine 
receptor activation (Vyas et al. 2016). This is notable since hexokinases influence 
mitochondrial permeability transition pore opening and subsequent ischaemia/reperfusion 
injury via their interaction with VDAC1 (Calmettes et al. 2015). In this study, SWATHTM-MS 
analysis identified 11 proteins not previously identified as TG2 protein substrates (e.g. 
adenine phosphoribosyltransferase) and 20 known substrates (Table 1) in response to 
isoprenaline stimulation. It is beyond the scope of the present discussion to describe the 
biological functions/roles of all of these proteins but it is interesting to note that induction of 
protein S100-A6 expression by tumour necrosis factor-α attenuates apoptosis in cardiac 
myocytes, suggesting a role for this TG2 substrate in cardioprotection (Tsoporis et al. 
2008). Furthermore, five of the proteins, whose profile increased following isoprenaline 
stimulation, are involved with metabolism. Of these, it is notable that malate 
dehydrogenase is the primary enzyme in the malate-aspartate shuttle and recent studies 
have shown that inhibition of this important mitochondrial process is cardioprotective 
(Støttrup et al. 2010).  
   Further interrogation of the SWATH data identified a large number of proteins that 
displayed a pronounced decrease following treatment with isoprenaline, indicative of altered 
levels of transamidation of specific substrates and/or proteins interacting with them. It is 
notable that TG2 can catalyse simultaneous transamidation and deamidation of heat shock 
protein 20 and thus it is conceivable that β2-adrenoceptor-induced activation also promotes 
deamidation of TG2 substrates (Boros et al. 2006). Overall, these data have identified a 
large number of proteins whose elution profile from CaptAvidin™-agarose beads changes 
markedly in isoprenaline treated cells. Future work will explore the role of such TG2-
mediated modifications in the cellular functions and signalling pathways mediated by the β2-
adrenoceptor. 
   Further studies are also required to assess the temporal effects of hypoxia/reoxygenation 
on the cellular localization and transamidase activity of TG2. Whilst previous studies have 
identified mitochondrial TG2 substrates including the Bcl-2 family member Bax (Rodolfo et 
al. 2004) and adenine nucleotide translocator 1 (Malorni et al. 2009), it would be of interest 
to identify additional TG2 protein substrates that undergo cross-linking and/or incorporation 
of small molecule mono- and polyamines during hypoxia/reoxygenation in cardiomyocytes 
in order to clarify the mechanism(s) of TG2-mediated cell survival. In summary, we have 
shown for the first time that TG2 is involved in the A1 adenosine receptor and β2-
adrenoceptor-induced pharmacological pre- and post-conditioning. Furthermore, since A1 
adenosine receptor and β2-adrenoceptor-induced TG2 activation is ERK1/2 dependent it is 
conceivable that TG2 is a downstream effector of the Reperfusion Injury Salvage Kinase 
pathway. Future experiments will endeavour to determine how TG2 protects against 
hypoxia/reoxygenation-induced cell death in H9c2 cardiomyoblasts. 
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Figure legends 
 
Figure 1. A1 adenosine receptor-induced pharmacological pre-conditioning against 
hypoxia/reoxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated for 
30 min with DPCPX (1 µM) before the addition of CPA (100 nM) for 10 min prior to 8 h 
hypoxia (1% O2) followed by 18 h reoxygenation (H/R) or normoxia (NX). Cell viability was 
assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (A) and 
release of LDH into the culture medium (B). Caspase-3 activation was assessed via Western 
blotting using anti-activated caspase-3 antibody (C) and quantified (D). Data are expressed 
as a percentage of normoxia control cell values (=100%) and represent the mean  S.E.M. 
from four independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, 
(a) versus normoxia control, (b) versus H/R control, (c) versus CPA alone in the presence of 
H/R. 
 
Figure 2. Knockdown of endogenous TG2 by siRNA. H9c2 cells (6-well plate; 45,000 
cells/well) were transfected for 48 h with 1 µM TG2 siRNA or negative control siRNA using 
Accell delivery medium. Control cells were cultured for 48 h in fully supplemented DMEM. 
(A) Levels of TG2 were subsequently assessed by Western blotting. Levels of β-actin are 
included for comparison. (B) Quantified data expressed as the ratio of TG2 to β-actin and 
represent  the mean  S.E.M. of three independent experiments. **P<0.01 versus Accell 
delivery medium control. 
 
Figure 3. The role of TG2 in A1 adenosine receptor induced pharmacological pre-
conditioning against hypoxia/reoxygenation-induced cell death. Where indicated, cells were 
pre-treated with TG2 inhibitors (Z-DON (150 μM) or R283 (200 μM)) for 1 h or for 48 h with 
1 µM TG2 siRNA or negative control siRNA before the addition of CPA (100 nM) for 10 min 
prior to 8 h hypoxia (1% O2) followed by 18 h reoxygenation (H/R) or normoxia (NX). Cell 
viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A,E) and release of LDH into the culture medium (B,F). Caspase-3 
activation was assessed via Western blotting using anti-activated caspase-3 antibody (C) 
and quantified (D). Data are expressed as a percentage of normoxia control cell values 
(=100%) and represent the mean  S.E.M. from four independent experiments. *P0.05, 
**P<0.01, ***P<0.001 and ****P0.0001, (a) versus normoxia control, (b) versus H/R 
control, (c) versus CPA alone in the presence of H/R. 
 
Figure 4. A1 adenosine receptor-induced pharmacological post-conditioning against 
hypoxia/reoxygenation-induced cell death. Following 8 h hypoxia cells were treated with the 
CPA (100 nM) for 10 min at the start of reoxygenation. Where appropriate, cells were pre-
treated with DPCPX (1 μM) for 30 min prior to stimulation with CPA.  Cell viability was 
assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (A) and 
release of LDH into the culture medium (B). Caspase-3 activation was assessed via Western 
blotting using anti-activated caspase-3 antibody (C) and quantified (D). Data are expressed 
as percentage of normoxic control (=100%) and represent the mean ± S.E.M. from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001, and ****P<0.0001, (a) versus 
normoxia control response, (b) versus H/R control, (c) versus CPA alone in the presence of 
H/R. 
 
Figure 5. The role of TG2 in A1 adenosine receptor-induced pharmacological post-
conditioning against hypoxia/reoxygenation-induced cell death. Following 8 h hypoxia cells 
were treated with the CPA (100 nM) for 10 min at the start of reoxygenation. Where 
indicated, cells were pre-treated with TG2 inhibitors (Z-DON (150 μM) or R283 (200 μM)) 
for 1 h or for 48 h with 1 µM TG2 siRNA or negative control siRNA prior to stimulation with 
CPA. Cell viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A,E) and release of LDH into the culture medium (B,F). Caspase-3 
activation was assessed via Western blotting using anti-activated caspase-3 antibody (C) 
and quantified (D). Data are expressed as percentage of normoxic control (=100%) and 
represent the mean ± S.E.M. from four independent experiments. *P0.05, **P<0.01, 
***P<0.001, and ****P<0.0001, (a) versus normoxia control response, (b) versus H/R 
control, (c) versus CPA alone in the presence of H/R. 
 
Figure 6. The effect of pharmacological pre-conditioning with formoterol and isoprenaline 
on hypoxia/reoxygenation-induced cell death. Where indicated, H9c2 cells were pre-treated 
for 30 min with ICI 118,551 (1 µM) or propranolol (1 µM) before the addition of formoterol 
(1 µM) or isoprenaline (10 µM) for 20 min prior to 8 h hypoxia (1% O2) followed by 18 h 
reoxygenation (H/R) or normoxia (NX). Cell viability was assessed by measuring the 
metabolic reduction of MTT by cellular dehydrogenases (A,C) and release of LDH into the 
culture medium (B,D). Caspase-3 activation was assessed via Western blotting using anti-
activated caspase-3 antibody (E) and quantified (F). Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean  S.E.M. from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) versus 
normoxia control, (b) versus H/R control, (c) versus isoprenaline alone in the presence of 
H/R. 
 
Figure 7. The role of Gi/o-proteins in isoprenaline-induced pharmacological pre-conditioning 
against hypoxia/reoxygenation-induced cell death. Where indicated, cells were pre-treated 
for 16 h with pertussis toxin (PTX; 100 ng/ml) before the addition of isoprenaline (10 µM) 
for 20 min prior to 8 h hypoxia (1% O2) followed by 18 h reoxygenation (H/R) or normoxia 
(NX). Cell viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A) and release of LDH into the culture medium (B). Caspase-3 activation 
was assessed via Western blotting using anti-activated caspase-3 antibody (C) and 
quantified (D). Data are expressed as a percentage of normoxia control cell values (=100%) 
and represent the mean  S.E.M. from four independent experiments. *P0.05, **P<0.01, 
***P<0.001 and ****P0.0001, (a) versus normoxia control, (b) versus H/R control, (c) 
versus isoprenaline alone in the presence of H/R. 
 
Figure 8. The role of TG2 in isoprenaline-induced pharmacological pre-conditioning against 
hypoxia/reoxygenation-induced cell death. Where indicated, cells were pre-treated with TG2 
inhibitors (Z-DON (150 μM) or R283 (200 μM)) for 1 h or for 48 h with 1 µM TG2 siRNA or 
negative control siRNA before the addition of isoprenaline (10 µM) for 20 min prior to 8 h 
hypoxia (1% O2) followed by 18 h reoxygenation (H/R) or normoxia (NX). Cell viability was 
assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (A,E) 
and release of LDH into the culture medium (B,F). Caspase-3 activation was assessed via 
Western blotting using anti-activated caspase-3 antibody (C) and quantified (D). Data are 
expressed as percentage of normoxic control (=100%) and represent the mean ± S.E.M. 
from four independent experiments. **P<0.01, ***P<0.001, and ****P<0.0001, (a) 
versus normoxia control response, (b) versus H/R control, (c) versus isoprenaline alone in 
the presence of H/R. 
 
Figure 9. Effect of isoprenaline on TG2 transamidase activity in H9c2 cells. (A) Cells were 
stimulated with isoprenaline (10 µM) for the indicated time periods. (B) Concentration-
response curve for isoprenaline in cells treated with agonist for 20 min. (C) Cells were pre-
treated for 30 min with the antagonists ICI 118,551 (1 µM) and propranolol (1 µM) or (D) 
for 1 h with the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) prior to stimulation with 
isoprenaline (ISO; 10 µM; 20 min). (E) Where indicated H9c2 cells were pre-treated for 16 
h with 100 ng/ml pertussis toxin (PTX) prior to 20 min stimulation with 10 µM isoprenaline. 
(F) Cells were pre-treated with PD 98059 (50 µM) for 30 min prior to 20 min stimulation 
with 10 µM isoprenaline.  Cell lysates were subjected to the biotin-cadaverine incorporation 
assay and data points represent the mean ± S.E.M. for TG2 specific activity from four 
independent experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) versus 
control response and (b) versus isoprenaline alone. 
 
Figure 10. Isoprenaline-induced cAMP accumulation in H9c2 cells. Where indicated, cells 
were pre-treated for 16 h with 100 ng/ml pertussis toxin (PTX) prior to stimulation for 20 
min with the indicated concentrations of isoprenaline. Levels of cAMP were determined as 
described in Materials and Methods. Data are presented as levels of cAMP in nM. The results 
represent the mean  S.E.M. of four experiments each performed in triplicate. *P0.05, 
**P<0.01, and ****P<0.0001 versus control. 
 
Figure 11. The effect of pharmacological post-conditioning with isoprenaline on 
hypoxia/reoxygenation-induced cell death. Following 8 h hypoxia cells were treated with the 
isoprenaline (10 µM) for 20 min at the start of reoxygenation. Where indicated, H9c2 cells 
were pre-treated for 30 min with ICI 118,551 (1 µM) or propranolol (1 µM) prior to 
stimulation with isoprenaline. Cell viability was assessed by measuring the metabolic 
reduction of MTT by cellular dehydrogenases (A) and release of LDH into the culture 
medium (B). Caspase-3 activation was assessed via Western blotting using anti-activated 
caspase-3 antibody (C) and quantified (D). Data are expressed as a percentage of normoxia 
control cell values (=100%) and represent the mean  S.E.M. from four independent 
experiments. *P0.05, **P<0.01, ***P<0.001 and ****P0.0001, (a) versus normoxia 
control, (b) versus H/R control, (c) versus isoprenaline alone in the presence of H/R. 
 
Figure 12. The role of Gi/o-proteins in isoprenaline-induced pharmacological post-
conditioning against hypoxia/reoxygenation-induced cell death. Following 8 h hypoxia cells 
were treated with the isoprenaline (10 µM) for 20 min at the start of reoxygenation. Where 
indicated, cells were pre-treated for 16 h with pertussis toxin (PTX; 100 ng/ml) prior to 
stimulation with isoprenaline. Cell viability was assessed by measuring the metabolic 
reduction of MTT by cellular dehydrogenases (A) and release of LDH into the culture 
medium (B). Caspase-3 activation was assessed via Western blotting using anti-activated 
caspase-3 antibody (C) and quantified (D). Data are expressed as a percentage of normoxia 
control cell values (=100%) and represent the mean  S.E.M. from four independent 
experiments. *P0.05, ***P<0.001 and ****P0.0001, (a) versus normoxia control, (b) 
versus H/R control, (c) versus isoprenaline alone in the presence of H/R. 
 
Figure 13. The role of TG2 in isoprenaline-induced pharmacological post-conditioning 
against hypoxia/reoxygenation-induced cell death. Following 8 h hypoxia cells were treated 
with the isoprenaline (10 µM) for 20 min at the start of reoxygenation. Where indicated, 
cells were pre-treated with TG2 inhibitors (Z-DON (150 μM) or R283 (200 μM)) for 1 h or for 
48 h with 1 µM TG2 siRNA or negative control siRNA prior to stimulation with isoprenaline. 
Cell viability was assessed by measuring the metabolic reduction of MTT by cellular 
dehydrogenases (A,E) and release of LDH into the culture medium (B,F). Caspase-3 
activation was assessed via Western blotting using anti-activated caspase-3 antibody (C) 
and quantified (D). Data are expressed as percentage of normoxic control (=100%) and 
represent the mean ± S.E.M. from four independent experiments. *P0.05, **P<0.01, 
***P<0.001, and ****P<0.0001, (a) versus normoxia control response, (b) versus H/R 
control, (c) versus  isoprenaline alone in the presence of H/R. 
 
Figure 14. Detection of biotin-X-cadaverine into protein S100-A6 following isoprenaline 
treatment of H9c2 cells. (A) Cells were incubated with 1 mM biotin-X-cadaverine for 6 h 
after which they were treated with isoprenaline (10 µM) for 20 min. Where indicated, cells 
were pre-treated with TG2 inhibitors Z-DON (150 μM) or R283 (200 μM) for 1 h prior to 
stimulation with isoprenaline. Biotin-X-cadaverine-labelled proteins were enriched using 
CaptAvidin™ agarose sedimentation beads and eluted proteins subjected to 
immunoprecipitation using anti-protein S100-A6 antibody. Immunoprecipitated proteins 
were subjected to SDS-PAGE, transferred to nitrocellulose membrane and detected using 
ExtrAvidin®-HRP. Immunoprecipitated samples were also analysed on separate blots using 
anti-protein S100-A6 antibody to confirm equal protein loading. (B) Quantified data are 
expressed as the percentage of biotinylated protein S100-A6 in control cells (= 100%) and 
represent the mean  S.E.M. of three independent experiments. *P0.05 and **P<0.01, (a) 
versus control response, (b) versus 10 µM isoprenaline alone. 
 
  
Table 1. Identification of proteins showing increased or decreased levels in eluates from 
CaptAvidin™-agarose columns following isoprenaline-induced  β2-adrenoceptor activation. 
Protein Name Uniprot 
Accession 
Uniprot 
Name 
Absolute 
Fold 
Change* 
Isoprenaline-induced increases    
bAdenine phosphoribosyltransferase P36972 APT_RAT 2.61 
aProtein S100-A6 P05964 S10A6_RAT 2.46 
eCollagen alpha-1(III) chain P13941 CO3A1_RAT 2.27 
gAnnexin A5 P14668 ANXA5_RAT 2.15 
hProtein disulfide-isomerase A5 Q5I0H9 PDIA5_RAT 2.02 
aProtein SET Q63945 SET_RAT 2.01 
bMalate dehydrogenase, mitochondrial P04636 MDHM_RAT 1.96 
eCollagen alpha-1(I) chain P02454 CO1A1_RAT 1.91 
bAcetyl-CoA carboxylase 1 P11497 ACACA_RAT 1.81 
bL-lactate dehydrogenase A chain P04642 LDHA_RAT 1.75 
gCaspase recruitment domain-containing protein 9 Q9EPY0 CARD9_RAT 1.74 
bAldehyde dehydrogenase, mitochondrial P11884 ALDH2_RAT 1.73 
dRibonuclease inhibitor P29315 RINI_RAT 1.71 
    
Isoprenaline-induced decreases    
d40S ribosomal protein S24 P62850 RS24_RAT -2.88 
dTranscription intermediary factor 1-beta O08629 TIF1B_RAT -2.87 
fPDZ and LIM domain protein 5 Q62920 PDLI5_RAT -2.60 
dCysteine and glycine-rich protein 1 P47875 CSRP1_RAT -2.47 
gLactadherin P70490 MFGM_RAT -2.24 
eDynactin subunit 2 Q6AYH5 DCTN2_RAT -1.90 
dElongation factor 1-delta Q68FR9 EF1D_RAT -1.88 
aTransforming growth factor beta-1-induced transcript 1 
protein 
Q99PD6 TGFI1_RAT -1.82 
eDynactin subunit 1 P28023 DCTN1_RAT -1.80 
aIntegrin beta-1 P49134 ITB1_RAT -1.79 
cVimentin P31000 VIME_RAT -1.78 
dEukaryotic translation initiation factor 5 Q07205 IF5_RAT -1.68 
eCytoplasmic dynein 1 heavy chain 1 P38650 DYHC1_RAT -1.57 
hHeat shock protein HSP 90-alpha P82995 HS90A_RAT -1.56 
cTubulin beta-4B chain Q6P9T8 TBB4B_RAT -1.52 
bFatty acid synthase P12785 FAS_RAT -1.42 
f14-3-3 protein theta P68255 1433T_RAT -1.42 
f14-3-3 protein zeta/delta P63102 1433Z_RAT -1.38 
 
H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with isoprenaline 
(10 µM) and biotin-cadaverine labelled proteins were captured and analysed by SWATH MS. 
*Absolute fold changes in isoprenaline-treated samples versus control (n=4) were calculated 
using SCIEX OneOmics with parameters MLR weight > 0.15, confidence >70%,  algorithms 
used described by Lambert et al., (2013). Known TG2 targets appearing in the TG2 
substrate database (Csósz et al., 2009) or identified by Yu et al. (2015), Almami et al. 
(2014), Vyas et al. (2016, 2017) are indicated in italics. Proteins are grouped according to 
their functions and/or cellular function as follows: acell signalling; bmetabolism; 
ccytoskeletal; dtranscription/translation; evesicular trafficking/extracellular matrix 
constituent; fstructural/scaffolding protein; gapoptosis; hprotein folding  
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